021-51111890
购物车（）
sales@molnova.cn
A-68930 hydrochloride
CAS No. 130465-39-3
A-68930 hydrochloride ( A68930 )
产品货号. M11221 CAS No. 130465-39-3
A-68930 is a potent, specific, orally bioavailable agonist of the D1 Dopamine receptor with EC50 of 2.5 nM.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥2219 | 有现货 |
|
| 50MG | ￥8068 | 有现货 |
|
| 100MG | ￥12798 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称A-68930 hydrochloride
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述A-68930 is a potent, specific, orally bioavailable agonist of the D1 Dopamine receptor with EC50 of 2.5 nM.
-
产品描述A-68930 is a potent, specific, orally bioavailable agonist of the D1 Dopamine receptor with EC50 of 2.5 nM; shows a much weaker agonist (EC50=3,920 nM) at the D2 dopamine receptor; demonstrates antidepressant and anorectic effects in animal models without stimulant effects.Heart Failure Discontinued
-
同义词A68930
-
通路GPCR/G Protein
-
靶点Dopamine Receptor
-
受体Dopamine Receptor
-
研究领域Neurological Disease
-
适应症——
化学信息
-
CAS Number130465-39-3
-
分子量307.77
-
分子式C16H17NO3 · HCl
-
纯度>98% (HPLC)
-
溶解度——
-
SMILESC1C(OC(C2=C1C(=C(C=C2)O)O)CN)C3=CC=CC=C3.Cl
-
化学全称1H-2-Benzopyran-5,6-diol, 1-(aminomethyl)-3,4-dihydro-3-phenyl-, hydrochloride, (1R,3S)-rel- (9CI)
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Kebabian JW, et al. Am J Hypertens. 1990 Jun;3(6 Pt 2):40S-42S.
2. Trampus M, et al. Eur J Pharmacol. 1993 Apr 22;235(1):83-7.
3. AI-Naser HA, et al. Behav Pharmacol. 1994 Apr;5(2):210-218.
2. Trampus M, et al. Eur J Pharmacol. 1993 Apr 22;235(1):83-7.
3. AI-Naser HA, et al. Behav Pharmacol. 1994 Apr;5(2):210-218.
产品手册
关联产品
-
3-CPMT
3-CPMT is a dopamine uptake inhibitor and a potent long-acting antihistaminic agent.
-
L-DOPA methyl ester ...
L-DOPA methyl ester (LDME) is an agonist of dopamine D1 receptor.
-
Hirsuteine
Hirsuteine is a natural product. It non-competitively antagonizes nicotine-mediated dopamine release by blocking ion permeation through nicotinic receptor channel complexes.
